04-02-2022, 10:08 AM
Nobody plans to do boosters all the time now.
At the beginning of the week there were talks with scientists in Israel, from which it became clear that a fourth vaccination made sense. Mertens referred to a study that proves this.
The protection against a serious illness also decreases after the third dose, so one has to consider "how to build up the protection again". This should happen with the fourth vaccination: "We are currently facing a mountain and want this mountain to roll over us lightly."
Criticism of the Stiko recommendation came from Thomas Voshaar, chief physician at the clinic for lung and bronchial medicine at the Bethanien Hospital in Moers: "I see no indication for a fourth vaccination with the same vaccine," he said in an interview with WELT.
"We forget that this vaccine was developed for the original virus," says Voshaar. He referred to the possible risks of the decision: "On the one hand, there is the question of whether this really has an additional positive effect. On the other hand, in view of possible side effects, it is completely unclear whether the benefit-risk ratio is still the same as with the first, second or third vaccination.”
The panel also stated "that the data on the effectiveness and safety of a second booster vaccination is still limited".
The preparation Nuvaxovid from the US manufacturer Novavax, which has been approved in the EU since the end of December, is – unlike the other approved vaccines – a protein vaccine with an effect enhancer.
"In the approval studies, the vaccine showed an efficacy comparable to that of the mRNA vaccines," Stiko explained.
However, no statements can yet be made on the clinical effectiveness against the omicron variant.
https://www.welt.de/politik/deutschland/...vavax.html
At the beginning of the week there were talks with scientists in Israel, from which it became clear that a fourth vaccination made sense. Mertens referred to a study that proves this.
The protection against a serious illness also decreases after the third dose, so one has to consider "how to build up the protection again". This should happen with the fourth vaccination: "We are currently facing a mountain and want this mountain to roll over us lightly."
Criticism of the Stiko recommendation came from Thomas Voshaar, chief physician at the clinic for lung and bronchial medicine at the Bethanien Hospital in Moers: "I see no indication for a fourth vaccination with the same vaccine," he said in an interview with WELT.
"We forget that this vaccine was developed for the original virus," says Voshaar. He referred to the possible risks of the decision: "On the one hand, there is the question of whether this really has an additional positive effect. On the other hand, in view of possible side effects, it is completely unclear whether the benefit-risk ratio is still the same as with the first, second or third vaccination.”
The panel also stated "that the data on the effectiveness and safety of a second booster vaccination is still limited".
The preparation Nuvaxovid from the US manufacturer Novavax, which has been approved in the EU since the end of December, is – unlike the other approved vaccines – a protein vaccine with an effect enhancer.
"In the approval studies, the vaccine showed an efficacy comparable to that of the mRNA vaccines," Stiko explained.
However, no statements can yet be made on the clinical effectiveness against the omicron variant.
https://www.welt.de/politik/deutschland/...vavax.html